Bridging advanced precision oncology with health system realities in the Philippines
13 Oct 2026
By Herdee Gloriane C. Luna,* MD, FPCP, FPSMO, FPSO
(Note: This article, in partnership with the Philippine Society of Medical Oncology, appeared in the MIMS Oncology magazine, October–November 2026 issue.)
In 2022, the Philippines recorded over 188,000 new cancer cases and113,000 deaths. The WHO Global Status Report on Cancer 2026 highlights a critical reality: the primary challenge in global oncology is no longer a gap in knowledge, but a gap in health system implementation. That gap is visible locally. Screening uptake varies with health-system readiness. Patients face long diagnostic journeys, fragmented work-up, and heavy out-of-pocket costs. Specialist care remains urban-concentrated, so distance, transport, and lost income become hidden barriers for provincial patients. Delay accumulates at each milestone—symptom to diagnosis, diagnosis to treatment plan, plan to treatment start, start to completion—driven by awareness gaps, pathology turnaround, financing approval, and stock-outs. Tracking these waiting times is what makes equity measurable.
Financing reform has made real progress. PhilHealth’s Z Benefit and related packages now cover breast cancer treatment up to PHP1.4 million and cervical cancer up to PHP175,000 in recent updates, while the YAKAP program has expanded to include cancer screening support for breast, liver, lung, and colorectal cancers. The more urgent question is no longer whether a package exists, but whether a patient can actually reach, activate, and complete it—a question that depends on referral pathways, treatment authorization support, pharmacy readiness, and patient navigation working together.
Activating this financial aid requires navigating the Medical and Financial Assistance to Indigent and Financially Incapacitated Patients (MAIFIP) Program order of charging. After applying mandatory privileged deductions such as Senior Citizen or PWD discounts, coverage begins with PhilHealth, followed by private HMOs if applicable. Remaining balances are routed through the DOH Social Health Protection Programs like the Cancer Assistance Fund, the MAIFIP Program itself, and other national or LGU assistance programs, with any residual costs covered by Quantified Free Service at the host hospital.
*Fellow, Philippine Society of Medical Oncology (PSMO), Philippine Society of Oncologists (PSO), and Philippine College of Physicians (PCP); Consultant, National Kidney and Transplant Institute (NKTI), St. Luke’s Medical Center, Quezon City (SLMC-QC), and Lung Center of the Philippines (LCP); email: herdeeluna@gmail.com
(Note: This article, in partnership with the Philippine Society of Medical Oncology, appeared in the MIMS Oncology magazine, October–November 2026 issue.)
In 2022, the Philippines recorded over 188,000 new cancer cases and113,000 deaths. The WHO Global Status Report on Cancer 2026 highlights a critical reality: the primary challenge in global oncology is no longer a gap in knowledge, but a gap in health system implementation. That gap is visible locally. Screening uptake varies with health-system readiness. Patients face long diagnostic journeys, fragmented work-up, and heavy out-of-pocket costs. Specialist care remains urban-concentrated, so distance, transport, and lost income become hidden barriers for provincial patients. Delay accumulates at each milestone—symptom to diagnosis, diagnosis to treatment plan, plan to treatment start, start to completion—driven by awareness gaps, pathology turnaround, financing approval, and stock-outs. Tracking these waiting times is what makes equity measurable.
Financing reform has made real progress. PhilHealth’s Z Benefit and related packages now cover breast cancer treatment up to PHP1.4 million and cervical cancer up to PHP175,000 in recent updates, while the YAKAP program has expanded to include cancer screening support for breast, liver, lung, and colorectal cancers. The more urgent question is no longer whether a package exists, but whether a patient can actually reach, activate, and complete it—a question that depends on referral pathways, treatment authorization support, pharmacy readiness, and patient navigation working together.
Activating this financial aid requires navigating the Medical and Financial Assistance to Indigent and Financially Incapacitated Patients (MAIFIP) Program order of charging. After applying mandatory privileged deductions such as Senior Citizen or PWD discounts, coverage begins with PhilHealth, followed by private HMOs if applicable. Remaining balances are routed through the DOH Social Health Protection Programs like the Cancer Assistance Fund, the MAIFIP Program itself, and other national or LGU assistance programs, with any residual costs covered by Quantified Free Service at the host hospital.
*Fellow, Philippine Society of Medical Oncology (PSMO), Philippine Society of Oncologists (PSO), and Philippine College of Physicians (PCP); Consultant, National Kidney and Transplant Institute (NKTI), St. Luke’s Medical Center, Quezon City (SLMC-QC), and Lung Center of the Philippines (LCP); email: herdeeluna@gmail.com